TY - JOUR T1 - Timing of relapse of tuberculosis in people with co-infection (HIV/TB) JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.492 VL - 56 IS - suppl 64 SP - 492 AU - Elena Filatova AU - Irina Vasilyevа AU - Vadim Testov AU - Igor Medvinskiy AU - Andry Senin Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/492.abstract N2 - Background: tuberculosis (TB) relapse occurs more frequently and faster in HIV patients compared with HIV-negative. However, HIV patients have different immune status (IS), as well as effective and ineffective antiretroviral therapy (ART).Objective: To study the effect of the level of IS and the effectiveness of ART on the rate of development of TB relapse in people with co-infection (HIV/TB).Materials and Methods: 2 groups of patients with TB relapse were studied, 104 of them with co-infection (HIV/TB) (1 gr.) and 101 without HIV (2 gr.). Duration of TB remission was estimated in both groups in months (m). The effectiveness of ART was evaluated according to the virological criterion. Patients without ART and with ineffective ART were considered together, since national clinical guidelines for all persons with co-infection (HIV/TB) prescribe ART.Results: It was found that TB relapse in patients of the 1 gr.in comparison with the 2nd gr. develops faster (31.5 ± 12.4 m. and 55.1 ± 21.8 m., p <0.001), but with CD4 + ≥350 cells/μl, there was no significant difference in the duration of remission between the groups (42.8 ± 15.3 m. and 55.1 ± 21.8 m., p = 0.176), as well as in patients with effective ART (37.8 ± 14.6 m. and 55.1 ± 21.8 m, p = 0.095). With a CD 4+ value <350 cells/μl in HIV-infected patients, TB relapse developed faster than in HIV-negative patients (21.2 ± 11.3 m. and 55.1 ± 21.8 m, p = 0.001), as well as with ineffective ART (27.9 ± 11.4 m. and 55.1 ± 21.8 m., p = 0.001).Conclusion: HIV patients with IS <350 cells/μ and ineffective ART have a high risk of rapid TB relapse, while in patients with CD 4+ cells ≥ 350 cell/µl and effective ART, the risks of TB relapse are similar with HIV negative.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 492.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -